Michael Lanuti MD | Thoracic Surgical Oncology | NSCLC, Sleeve Resection, Diagnosis & Treatment

18:44
 
Поширити
 

Manage episode 328617831 series 3302009
Зроблено PrecisCa і знайдено завдяки Player FM та нашій спільноті. Авторські права належать видавцю, а не Player FM, і аудіоматеріали транслюються безпосередньо з сервера видавця. Натисніть на кнопку Підписатися, щоб слідкувати за оновленнями в Player FM або скопіюйте і вставте посилання на канал до іншої програми для подкастів.

On this episode, PrecisCa speaks with Dr. Michael Lanuti, an Associate Professor of Surgery at Harvard Medical School & the Director of Thoracic Oncology, Division of Thoracic Surgery at Massachusetts General Hospital.

Dr. Lanuti sits down with PrecisCa to discuss the following:

  • What tests need to be ordered before surgery for lung cancer?
  • Which patient should not undergo surgery for lung cancer?
  • What is a sleeve resection?
  • What is the role of pulmonary function testing and who should be tested?
  • How many days do patients spend in the hospital with various types of lung surgery?
  • What are the average operative times for Surgical Techniques in Lung Cancer?
  • What are some common complaints after a patient has undergone lung surgery?

Dr. Lanuti is the Director of Thoracic Oncology for the Division of Thoracic Surgery and the Thoracic Surgery liaison to the MGH Cancer Center. Clinical interests include minimally invasive surgery for lung cancer, complex airway tumors, multimodality treatment of esophageal cancer, mediastinal tumors, navigation and robotic bronchoscopy, non surgical treatment of lung tumors using percutaneous and bronchoscope thermal ablation techniques.

Dr. Lanuti spearheads translational research in a Thoracic Oncology Research Laboratory. The principle goals of the laboratory are to design novel therapeutics to treat lung and esophageal cancer that can be brought to clinical trials. The laboratory uses oncolytic viruses in combination with other modalities such as chemotherapy and angiotensin system inhibitors to target solid tumor. Some of these strategies include development of oncolytic viruses that help degrade tumor matrix. Ultimately, this translational effort will strive to bring treatment strategies from the laboratory bench to the bedside and back to the bench again for re-evaluation and improvement.

Dr. Lanuti has investigated molecular risk factors for esophageal adenocarcinoma and found an elevated risk associated with single nucleotide polymorphisms in the epidermal growth factor (EGF) gene which is associated with differentiation of tumor tissue

After receiving a Bachelor of Science in Bioengineering from the University of Pennsylvania, Dr. Lanuti received his M.D. degree from the University of Pennsylvania School of Medicine. He completed his internship and residency in Surgery at the Hospital of the University of Pennsylvania and a 2-year research fellowship in a Thoracic Oncology Laboratory focusing on novel treatments for lung cancer.

Dr. Lanuti continued with sub-specialty training and completed a Cardiothoracic Fellowship at the Massachusetts General Hospital. He has been on staff in the Division of Thoracic Surgery since 2004 and holds a parallel appointment as Associate Professor of Surgery at Harvard Medical School. He has been the Friedman-Lambert Scholar in Academic Thoracic Surgery at MGH/HMS since 2004 and directs a Thoracic Oncology Research Lab for the past 15 years focusing on novel treatment of lung cancer, pulmonary fibrosis and imaging of radiation induced lung injury in the setting of lung cancer.

Visit www.precisca.com for more resources, content, and access to our entire catalogue of educational content. There you will have access to our complete library of educational videos. New episodes of the PrecisCa Oncology Podcast are released weekly. Please consider sharing our podcast, subscribing & turning on notifications to be the first to know about new releases. Together, we can raise the level of cancer care from diagnosis to recovery.

19 епізодів